Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...

The clearance gives New York clinicians access to the Haystack MRD assay, which detects residual or recurring solid tumour ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces expanded availability of Precise MRD™, broadening availability to patients ...

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack ...

Natera recently announced that its Signatera minimal residual disease (MRD) test received approval from Japan’s Pharmaceuticals and Medical Devices Agency for use in colorectal cancer patients in the ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed molecular ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice ...

Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, ...

Add Yahoo as a preferred source to see more of our stories on Google. New prospective sub-study analysis data presented by Abbott at the 2026 American Society of Clinical Oncology (ASCO) meeting has ...

A multiple myeloma survivor discusses how continued minimal residual disease negativity made her feel more confident in coming off of maintenance therapy. After undergoing treatment — including a stem ...